Profile data is unavailable for this security.
About the company
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. The Company specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. It operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.
- Revenue in EUR (TTM)762.99m
- Net income in EUR70.55m
- Incorporated2007
- Employees3.46k
- LocationFagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
- Phone+32 80012880
- Fax+32 92162491
- Websitehttps://fagron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caplin Point Laboratories Ltd | 186.32m | 50.27m | 1.28bn | 777.00 | 25.50 | 5.01 | 22.55 | 6.85 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | -- | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | -- |
| Cosmo Pharmaceuticals NV | 189.22m | 75.62m | 1.30bn | 339.00 | 15.72 | 2.38 | 14.31 | 6.84 | 4.51 | 4.51 | 11.28 | 29.80 | 0.2753 | 3.19 | 6.59 | 558,769.60 | 11.04 | 0.2437 | 13.52 | 0.267 | 76.96 | 57.28 | 40.11 | 2.10 | 4.48 | -- | 0.0029 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| Tibet Rhodiola Pharmaceutical Holding Co | 372.32m | 102.95m | 1.33bn | 601.00 | 11.55 | 2.20 | -- | 3.56 | 2.81 | 2.81 | 9.65 | 14.76 | 0.6016 | 1.81 | 6.68 | 4,877,892.00 | 16.83 | 12.44 | 23.18 | 15.71 | 93.68 | 90.51 | 27.97 | 20.43 | 2.79 | 7.96 | 0.1716 | 50.41 | 22.69 | 24.98 | 116.56 | 30.01 | -1.48 | 48.97 |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 816.18m | 66.48m | 1.36bn | 8.41k | 20.69 | 1.50 | -- | 1.67 | 0.202 | 0.202 | 2.49 | 2.78 | 0.5568 | 2.39 | 4.60 | 764,058.90 | 5.02 | 6.77 | 7.25 | 10.50 | 54.36 | 63.24 | 9.02 | 11.10 | 1.53 | 40.71 | 0.1459 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
| Fagron NV | 762.99m | 70.55m | 1.38bn | 3.46k | 19.43 | 2.96 | 12.74 | 1.80 | 0.9664 | 0.9664 | 10.45 | 6.35 | 0.7715 | 3.87 | 12.43 | 220,517.60 | 7.18 | 7.63 | 8.76 | 9.77 | 43.59 | 43.49 | 9.31 | 10.23 | 1.27 | 4.45 | 0.4395 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Biotest AG | 782.60m | 176.90m | 1.38bn | 2.43k | 9.40 | 3.15 | -- | 1.77 | 4.47 | 4.47 | 19.78 | 13.34 | 0.5936 | 1.14 | 3.83 | 322,588.60 | 13.42 | -0.0693 | 16.72 | -0.079 | 44.24 | 28.43 | 22.60 | -0.1527 | 0.9139 | 5.34 | 0.5677 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Tilray Brands Inc | 684.46m | -324.11m | 1.39bn | 1.60k | -- | 0.4217 | -- | 2.03 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.121 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Shanghai Henlius Biotech Inc | 687.03m | 69.53m | 1.44bn | 3.64k | 20.76 | 5.16 | 12.49 | 2.09 | 1.08 | 1.08 | 10.67 | 4.35 | 0.5731 | 1.95 | 9.10 | 1,601,376.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| Wockhardt Ltd | 307.73m | -50.92m | 1.44bn | 2.39k | -- | 3.90 | -- | 4.68 | -32.08 | -32.08 | 194.04 | 218.97 | 0.365 | 1.80 | 3.95 | 11,687,550.00 | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.26 | -16.87 | -12.70 | 0.5532 | -0.1594 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 136.35m | 44.73m | 1.44bn | 965.00 | 32.19 | 2.27 | -- | 10.56 | 0.571 | 0.571 | 1.74 | 8.09 | 0.2078 | 1.14 | 9.25 | 1,112,527.00 | 6.61 | 1.32 | 6.93 | 1.41 | 77.85 | 80.74 | 31.81 | 6.55 | 6.66 | -- | 0.01 | 8.25 | 22.84 | -2.35 | 497.63 | -4.44 | 21.22 | -- |
| Nippon Shinyaku Co., Ltd. | 888.12m | 154.86m | 1.44bn | 2.21k | 8.92 | 1.05 | 7.79 | 1.62 | 383.80 | 383.80 | 2,201.17 | 3,269.71 | 0.592 | 1.33 | 3.27 | 66,991,870.00 | 10.32 | 10.45 | 12.09 | 12.31 | 66.12 | 61.27 | 17.44 | 16.47 | 3.35 | -- | 0.0129 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
| Mayinglong Pharmaceutical Group Co Ltd | 413.91m | 57.57m | 1.45bn | 2.88k | 25.13 | 2.91 | -- | 3.50 | 1.05 | 1.05 | 7.56 | 9.08 | 0.6482 | 5.87 | 11.13 | 1,130,851.00 | 9.26 | 10.82 | 11.03 | 13.47 | 42.87 | 41.18 | 14.29 | 14.08 | 5.18 | -- | 0.0729 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Chongqing Genrix Biophrmctcl Co Ltd | 141.97k | -97.05m | 1.46bn | 547.00 | -- | 4.32 | -- | 10,280.50 | -2.08 | -2.08 | 0.0031 | 7.25 | 0.0005 | 0.0231 | 19.76 | 2,043.55 | -35.10 | -- | -37.12 | -- | -17.40 | -- | -68,358.07 | -- | 23.66 | -493.94 | 0.1946 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
Data as of Jul 26 2024. Currency figures normalised to Fagron NV's reporting currency: Euro EUR
43.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Goldman Sachs Asset Management BVas of 31 Dec 2022 | 11.61m | 15.85% |
| Active Ownership Corp SARLas of 19 Dec 2023 | 8.10m | 11.07% |
| Mawer Investment Management Ltd.as of 31 Dec 2022 | 2.20m | 3.01% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 2.08m | 2.84% |
| Fidelity Management & Research Co. LLCas of 31 May 2024 | 1.95m | 2.67% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Jun 2024 | 1.40m | 1.92% |
| BNP Paribas Asset Management Belgium SAas of 30 Jun 2024 | 1.18m | 1.62% |
| Amundi Asset Management SA (Investment Management)as of 03 Jul 2024 | 1.17m | 1.60% |
| Tweedy, Browne Co. LLCas of 31 Mar 2024 | 1.12m | 1.53% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 1.06m | 1.45% |
More ▼
Data from 31 Mar 2024 - 17 Jul 2024Source: FactSet Research Systems Inc.
